Aclaris Therapeutics Inc. (ACRS)
Symbol Info
Listed Symbol ACRS
Name Aclaris Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $8,591,000
Latest Fiscal EPS $-4.04
Price Info
21 Day Moving Average $0.9902
21 Day EMA $1.073310
50 Day Moving Average $1.3776
50 Day EMA $1.662190
200 Day EMA $5.527770
200 Day Moving Average 5.055480
52 Week High $16.07
52 Week Low $0.74
52 Week Change $-93.165200
Alpha -0.043951
Beta 0.8112
Standard Deviation 0.186141
R2 0.021604
Periods 47
Share Information
10 Day Average Volume 595,088
20 Day Average Volume 758,305
30 Day Average Volume 1,193,038
50 Day Average Volume 1,019,433
Outstanding Shares 41,368,224
Float Shares 39,589,342
Percent Float 95.70%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 231
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 4,368,982
Institute Holdings Percent -
Institute Sold Previous 3 Months 7,775,952
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,778,882
Price Change
7 Day Price Change $0.0200000
7 Day Percent Change 1.98%
21 Day Price Change $-0.03
21 Day Percent Change -2.83%
30 Day Price Change $0.2023000
30 Day Percent Change 24.44%
Month To Date Price Change $0.0200
Month To Date Percent 1.98%
90 Day Price Change $-3.84
90 Day Percent Change -78.85%
Quarter To Date $-1.16
Quarter To Date Percent -52.97%
180 Day Price Change $-4.9
180 Day Percent Change -82.63%
200 Day Price Change $-5.54
200 Day Percent Change -84.32%
Year To Date $-6.36
Year To Date Percent -86.06%
Profile
Description Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.
Details
Issue Type CS
Market Cap $42,609,271
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 41,368,224
CEO Neal Walker
Employees 169
Last Audit UQ
Classification
CIK 0001557746
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 640 Lee Road
Suite 200
Wayne, PA 19087
Website http://www.aclaristx.com
Facisimile +1 484 320-2344
Telephone +1 484 324-7933
Email mtung@aclaristx.com
Key Ratios
Profitability
EBIT Margin -870.9
EBITDA Margin -835.1
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 37.20
Profit Margin TOT -
Income Statements
Revenue $15,703,000
Revenue Per Share $0.3796
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-39,924,319
Price To Sales 2.713448
Price To Free Cash -0.2
PE High Last 5 Years -
Price To Book 0.6
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.5
Financial Strength
Total Debt To Equity 0.2
Int Coverage -
Current Ratio 3.2
Leverage Ratio 1.4
Quick Ratio 3.2
Long Term Debt To Capital 0.18
Assets
Receivables Turnover 1.4
Invoice Turnover 16.80
Assets Turnover -
Management Effectiveness
Return Assets -75.76
Return On Equity -101.94
Return On Capital -85.15
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACRS
Aclaris Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.